Perez-Nieves M, et al. - Experts undertook a comparative analysis of the costs, resource utilization, and complications between adherent and nonadherent patients over the 3-year period post initiation on basal insulin therapy. Eligible candidates included adults aged 18 years or older with type 2 diabetes (T2D) who initiated therapy on basal insulin in 2012. Subjects who were adherent over time to basal insulin treatment therapy (33.8% of patients) had considerably higher diabetes-related drug costs 3 years after initiating therapy on basal insulin. Despite higher drug costs, findings revealed disease-specific and all-cause cost offsets as well as improved patient outcomes linked with adherence to basal insulin therapy for people with T2D.